Efficacy of Intermittent ADT with Degarelix, the New Gonadotrophin Releasing Hormone (GnRH) Antagonist

There has been much conversation surrounding the use of intermittent androgen deprivation (IAD) as opposed to continuous androgen deprivation (CAD) in men with prostate cancer who need hormone therapy (ADT). The question that has been at issue is if either method is superior to the other. There have been studies that have concluded that they [...]

Degarelix Monotherapy vs. Luteinizing Hormone-Releasing Hormone Agonists Plus Antiandrogen Flare Protection For Men With Advanced Prostate Cancer *

There are a number of different flavors of hormone therapy (ADT) used to treat advanced prostate cancer. However, they could be summed up and put into two different categories. 1- The use of luteinizing hormone-releasing hormone (LHRH) agonist therapy (drugs like Lupron and Zoladex) along with short term antiandrogen (AA) flare protection 2- Degarelix, a [...]

Dealing with A New Health Issue – A Rare Cancer Along with Prostate Cancer

My wife Wendy wrote a post to the advanced prostate cancer online support group where she discussed our recent experience re-entering the healthcare system to deal with a non-prostate cancer issue. In the post she shared that I have been diagnosed with a rare cancer, appendiceal cancer, specifically a mucinous cystadenocarcinoma. We have become very [...]

Using choline-C11 PET/CT Scans To Predict Survival In Men With Recurrent Prostate Cancer

Choline-C11 PET/CT scans can identify the actual sites of recurrence of prostate cancer in men who have a rising PSA after receiving primary therapy. The question worth asking is if this type of scan might be able to be used for prognostic purposes. Knowing this might influence our treatment decisions as well as our basic [...]

Go to Top